Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
An adsorbent for an oral administration, comprising a surface-modified spherical activated carbon wherein an average diameter is 0.01 to 1 mm, a specific surface area determined by a BET method is 700 m 2 /g or more, a volume of pores having a pore diameter of 7.5 to 15000 nm is from 0.25 mL/g to 1.0 mL/g, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 0.7 meq/g, is disclosed.
1. An adsorbent for an oral administration, comprising a surface-modified spherical activated carbon wherein the average diameter is 0.01 to 1 mm, a specific surface area determined by a BET method is 700 m 2 /g or more, a volume of pores having a pore diameter of 7.5 to 15000 nm is from 0.25 mL/g to 1.0 mL/g, a volume of pores having a pore diameter of 7.5 to less than 20 nm is from 0.10 mL/g to 0.19 mL/g, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 0.7 meq/g.
2. A pharmaceutical composition comprising a surface-modified spherical activated carbon wherein the average diameter is 0.01 to 1 mm, a specific surface area determined by a BET method is 700 m 2 /g or more, a volume of pores having a pore diameter of 7.5 to 15000 nm is from 0.25 mL/g to 1.0 mL/g, a volume of pores having a pore diameter of 7.5 to less than 20 nm is from 0.10 mL/g to 0.19 mL/g, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 0.7 meq/g.
3. The adsorbent for oral administration according to claim 1 , wherein a carbon source for the surface-modified spherical activated carbon is a heat fusible resin.
4. The adsorbent for oral administration according to claim 1 , wherein a carbon source for the surface-modified spherical activated carbon is a heat-infusible resin.
5. The adsorbent for oral administration according to claim 1 , wherein a carbon source for the surface-modified spherical activated carbon is a pitch.
6. The adsorbent for oral administration according to claim 1 , wherein the surface-modified spherical activated carbon is prepared by oxidizing a spherical activated carbon at 300-800° C. and then reducing the product at 800-1200° C.
7. The adsorbent for oral administration according to claim 1 , wherein the average diameter is 0.02 to 0.8 mm, a specific surface area determined by a BET method is from 1000-3000 m 2 /g, a volume of pores having a pore diameter of 7.5 to 15000 nm is from 0.3 mL/g to 0.8 mL/g, a volume of pores having a pore diameter of 7.5 to less than 20 nm is from 0.10 mL/g to 0.19 mL/g, and a total amount of basic groups is 0.30 to 0.60 meq/g.
8. A method for treating a renal disease, comprising administering to a subject in need thereof, a surface-modified spherical activated carbon wherein an average diameter is 0.01 to 1 mm, a specific surface area determined by a BET method is 700 m 2 /g or more, a volume of pores having a pore diameter of 7.5 to 15000 nm is from 0.25 mL/g to 1.0 mL/g, a volume of pores having a pore diameter of 7.5 to less than 20 nm is from 0.10 mL/g to 0.19 mL/g, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 0.7 meq/g.
9. The method according to claim 8 , wherein the renal disease is a disease selected from the group consisting of chronic renal failure, acute renal failure, chronic pyelonephritis, acute pyelonephritis, chronic nephritis, acute nephritic syndrome, acute progressive nephritic syndrome, chronic nephritic syndrome, nephrotic syndrome, nephrosclerosis, interstitial nephritis, tubulopathy, lipoid nephrosis, diabetic nephropathy, renovascular hypertension, and hypertension syndrome, secondary renal diseases caused by these primary diseases, and a light renal failure before a dialysis therapy.
10. A method for treating a liver disease, comprising administering to a subject in need thereof, a surface-modified spherical activated carbon wherein an average diameter is 0.01 to 1 mm, a specific surface area determined by a BET method is 700 m 2 /g or more, a volume of pores having a pore diameter of 7.5 to 15000 nm is from 0.25 mL/g to 1.0 mL/g, a volume of pores having a pore diameter of 7.5 to less than 20 nm is from 0.10 mL/g to 0.19 mL/g, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 0.7 meq/g.
11. The method according to claim 10 , wherein the liver disease is a disease selected from the group consisting of fulminant hepatitis, chronic hepatitis, viral hepatitis, alcoholic hepatitis, hepatic fibrosis, liver cirrhosis, hepatic cancer, autoimmune hepatitis, drug allergic hepatopathy, primary biliary cirrhosis, tremor, encephalopathia, dysbolism, and dysfunction.